Article Information
History
- July 1, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Mark J. Mulligan1,*,
- Kirsten E. Lyke2,*,
- Nicholas Kitchin*,3,a,
- Judith Absalon3,b,†,
- Alejandra Gurtman3,b,
- Stephen Lockhart3,a,
- Kathleen Neuzil2,
- Vanessa Raabe1,
- Ruth Bailey3,a,
- Kena A. Swanson3,b,
- Ping Li3,c,
- Kenneth Koury3,b,
- Warren Kalina3,b,
- David Cooper3,b,
- Camila Fontes-Garfias6,
- Pei-Yong Shi6,
- Ӧzlem Türeci7,
- Kristin R. Tompkins3,b,
- Edward E. Walsh4,
- Robert Frenck5,
- Ann R. Falsey4,
- Philip R. Dormitzer3,b,
- William C. Gruber3,b,
- Uğur Şahin7 and
- Kathrin U. Jansen3,b
- 1New York University Langone Vaccine Center and New York University Grossman School of Medicine, New York, NY
- 2University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore, MD
- 3Vaccine Research and Development, Pfizer
- 4University of Rochester and Rochester General Hospital, Rochester, NY
- 5Cincinnati Children’s Hospital, Cincinnati, OH
- 6University of Texas Medical Branch, Galveston, TX
- 7BioNTech, Mainz, Germany
- ↵†Corresponding author Correspondence to Judith Absalon, MD, MPH, FIDSA judith.absalon{at}pfizer.com
↵* contributed equally
Posted July 01, 2020.
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
